Pushing the boundaries of imaging technology

We’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

Clinical trial imaging

Pioneer of a new imaging diagnostic paradigm

We are transforming the imaging diagnostic world by developing the most accurate AI-powered digital biomarkers across multiple imaging modalities. Our focus is to achieve accurate early diagnosis to improve patient lives by helping radiologists and clinicians in their diagnostic workflow in oncology and metabolic diseases.

iBiopsy®

We deliver on a global scale

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.

Investors

Median's latest news

Fredrik Brag, CEO and founder of Median, provides additional insights on iBiopsy ® Lung Cancer Screening CADe/CADx Software as Medical Device (in French).

Watch video

Latest press releases

3 October 2022

Median Technologies announces formation of Clinical Advisory Board for iBiopsy® Lung Cancer Screening

The Clinical Advisory Board includes world class physicians and academic leaders in the space of lung cancer and will bring comprehensive expertise on Lung Cancer Screening to guide Median in the development of iBiopsy® LCS AI/ML tech-based CADe/CADx Software as Medical device.

6 September 2022

Median Technologies to participate in the 2022 ESMO Congress, Sep 9 – 13, 2022, Paris, France, with two scientific posters on iCRO and iBiopsy®

Median Technologies (ALMDT) announced today that the Company will be participating in the 2022 ESMO (European Society for Medical Oncology) Congress, to be held in Paris, France, September 9-13 (venue: Paris Expo Porte de Versailles).

11 July 2022

Median Technologies communicates its business indicators for the second quarter of 2022

Best ever quarterly revenues at €7 million, +43% vs YAGO – Order backlog on June 30th 2022 at €60 million, +14.3% vs YAGO, and Cash Position of €28.2 million (€39 million on Dec. 31st, 2021), despite adverse conditions caused by the lockdown in China

7 July 2022

Median Technologies to host a live webcast and provide a company update on July 12, 2022

Median Technologies (ALMDT:PA) announced today that Fredrik Brag, CEO and founder of Median Technologies, will provide a company update on July 12, 2022 at 11:00 am CEST during a webcast.

13 June 2022

Bryan Garnier & Co initiates the coverage of Median Technologies with a “Buy” recommendation

In the initiation report published on June 10, 2022, Bryan Garnier & Co initiates the coverage of the stock with a buy recommendation and values the company at 40 euros per share.

1/5

Our Winter Corporate Newsletter

We are pleased to share with you our Winter Corporate Newsletter, presenting our most recent announcements and what we did during the fourth quarter of 2021 and in early Q1 2022. Click below to read the Newsletter!

Webinars

JUNE 21st, 2022

Overcoming the challenges in deploying new imaging biomarkers in clinical trials – Perspectives from patients, physicians and other stakeholders

This webinar is jointly organized by Labcorp Drug Development and Median Technologies. New Imaging biomarkers have a strong potential to provide additional insight for clinical trials: better selection of patients, prediction of response to therapy, early assessments of drug effects and safety. However, implementing them in clinical trials often promote challenges.

The aim of this webinar is to discuss these challenges from the perspective of patients, physicians and the different stakeholders involved in the oncology clinical trials. Want to know more? Register now!

Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Read more

iBiopsy®

Enhancing imaging diagnostic accuracy

Our team of data scientists, AI engineers and clinicians is focused on developing the most accurate and cutting-edge AI-powered Software as a Medical Device (SaMD). iBiopsy® targets: lung cancer, liver cancer, and NASH to provide to patients an earlier and optimal diagnosis avoiding unnecessary invasive tests.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

Together, let's build the future of medicine

Contact us Jobs at Median